Detection of high-risk subtypes of human papillomavirus in cervical swabs: routine use of the Digene Hybrid Capture assay and polymerase chain reaction analysis.

Hdl Handle:
http://hdl.handle.net/10147/209087
Title:
Detection of high-risk subtypes of human papillomavirus in cervical swabs: routine use of the Digene Hybrid Capture assay and polymerase chain reaction analysis.
Authors:
Brennan, M M; Lambkin, H A; Sheehan, C D; Ryan, D D; O'Connor, T C; Kealy, W F
Affiliation:
Department of Histopathology, Cytology and Gynaecology, Cork University Hospital,, Wilton, Cork, Ireland.
Citation:
Br J Biomed Sci. 2001;58(1):24-9.
Journal:
British journal of biomedical science
Issue Date:
3-Feb-2012
URI:
http://hdl.handle.net/10147/209087
PubMed ID:
11284220
Abstract:
Human papillomaviruses (HPVs) are major causative agents in the pathogenesis of cervical cancer, and more than twenty types are associated with its development. With the introduction of liquid-based preparation systems, it is envisaged that large-scale HPV testing will be established in the near future. Preliminary studies demonstrate the accessibility of these samples for DNA testing using both the Digene Hybrid Capture assay (DHCA) and polymerase chain reaction (PCR) techniques. This study aims to assess the validity and sensitivity of the DHCA system to detect high-risk HPV DNA, using two sets of HPV consensus primers (Gp5+/Gp6+ and MY09/MY11) in tandem with routine assessment of cervical smear and biopsy samples. Results indicate that the combination of DHCA and PCR detects more high-grade lesions than does the DHCA alone. DHCA-negative cases were categorised by subsequent PCR amplification into low-grade HPV-negative (12/16) cervical lesions and high-grade HPV-positive (7/9) cervical lesions. Gp5+/Gp6+ primers were less sensitive in detecting HPV-positive samples than was the MY09/MY11 primer set. These results support the use of high-risk HPV testing by DHCA, with subsequent analysis of DHCA-negative samples by PCR using the MY09/MY11 primers.
Language:
eng
MeSH:
Adult; Cervix Uteri/*virology; DNA Primers; DNA, Viral/*analysis; Female; Humans; In Situ Hybridization/methods; Middle Aged; Papillomaviridae/*genetics; Polymerase Chain Reaction/methods; Risk; Sensitivity and Specificity; Uterine Cervical Neoplasms/virology; Vaginal Smears
ISSN:
0967-4845 (Print); 0967-4845 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorBrennan, M Men_GB
dc.contributor.authorLambkin, H Aen_GB
dc.contributor.authorSheehan, C Den_GB
dc.contributor.authorRyan, D Den_GB
dc.contributor.authorO'Connor, T Cen_GB
dc.contributor.authorKealy, W Fen_GB
dc.date.accessioned2012-02-03T15:11:56Z-
dc.date.available2012-02-03T15:11:56Z-
dc.date.issued2012-02-03T15:11:56Z-
dc.identifier.citationBr J Biomed Sci. 2001;58(1):24-9.en_GB
dc.identifier.issn0967-4845 (Print)en_GB
dc.identifier.issn0967-4845 (Linking)en_GB
dc.identifier.pmid11284220en_GB
dc.identifier.urihttp://hdl.handle.net/10147/209087-
dc.description.abstractHuman papillomaviruses (HPVs) are major causative agents in the pathogenesis of cervical cancer, and more than twenty types are associated with its development. With the introduction of liquid-based preparation systems, it is envisaged that large-scale HPV testing will be established in the near future. Preliminary studies demonstrate the accessibility of these samples for DNA testing using both the Digene Hybrid Capture assay (DHCA) and polymerase chain reaction (PCR) techniques. This study aims to assess the validity and sensitivity of the DHCA system to detect high-risk HPV DNA, using two sets of HPV consensus primers (Gp5+/Gp6+ and MY09/MY11) in tandem with routine assessment of cervical smear and biopsy samples. Results indicate that the combination of DHCA and PCR detects more high-grade lesions than does the DHCA alone. DHCA-negative cases were categorised by subsequent PCR amplification into low-grade HPV-negative (12/16) cervical lesions and high-grade HPV-positive (7/9) cervical lesions. Gp5+/Gp6+ primers were less sensitive in detecting HPV-positive samples than was the MY09/MY11 primer set. These results support the use of high-risk HPV testing by DHCA, with subsequent analysis of DHCA-negative samples by PCR using the MY09/MY11 primers.en_GB
dc.language.isoengen_GB
dc.subject.meshAdulten_GB
dc.subject.meshCervix Uteri/*virologyen_GB
dc.subject.meshDNA Primersen_GB
dc.subject.meshDNA, Viral/*analysisen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHumansen_GB
dc.subject.meshIn Situ Hybridization/methodsen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshPapillomaviridae/*geneticsen_GB
dc.subject.meshPolymerase Chain Reaction/methodsen_GB
dc.subject.meshRisken_GB
dc.subject.meshSensitivity and Specificityen_GB
dc.subject.meshUterine Cervical Neoplasms/virologyen_GB
dc.subject.meshVaginal Smearsen_GB
dc.titleDetection of high-risk subtypes of human papillomavirus in cervical swabs: routine use of the Digene Hybrid Capture assay and polymerase chain reaction analysis.en_GB
dc.contributor.departmentDepartment of Histopathology, Cytology and Gynaecology, Cork University Hospital,, Wilton, Cork, Ireland.en_GB
dc.identifier.journalBritish journal of biomedical scienceen_GB
dc.description.provinceMunster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.